Peptide Schedule
PEG-MGF24 residuesYQPPSTNKNTKSQRRKGSTFEERKEach bubble = one amino acid. Size = residue mass. Color = chemical class.PEG-MGF
Benefits
About PEG-MGF
PEG-MGF (Pegylated Mechano Growth Factor) is the PEGylated form of MGF, a splice variant of IGF-1 (specifically IGF-1Ec) produced in response to mechanical loading of muscle tissue. Native MGF has an extremely short half-life of approximately 5-7 minutes, making it impractical for therapeutic use. The addition of a polyethylene glycol (PEG) chain shields the peptide from enzymatic degradation and renal clearance, extending its half-life to approximately 48-72 hours. PEG-MGF activates quiescent muscle satellite (stem) cells, promoting their proliferation without triggering premature differentiation — a critical distinction from other growth factors like IGF-1 LR3, which primarily drives differentiation. This makes PEG-MGF a targeted tool for muscle repair and hypertrophy in preclinical research.
Who Should Consider PEG-MGF
- Athletes and bodybuilders seeking enhanced muscle recovery and hypertrophy
- Individuals recovering from exercise-induced or mechanical muscle damage
- Researchers studying satellite cell biology and muscle regeneration
- Adults interested in body recomposition with targeted muscle growth
- Users of GH secretagogue stacks looking to add a direct myogenic peptide
How PEG-MGF Works
PEG-MGF binds to receptors on muscle cells via its unique C-terminal E-peptide domain, activating quiescent satellite cells and driving their proliferation through a pathway largely independent of the classical IGF-1 receptor. The E-peptide down-regulates MyoD and p21, keeping satellite cells in a proliferative state and delaying differentiation. This priming phase expands the pool of myogenic precursor cells available for repair. Once PEG-MGF levels decrease, mature IGF-1 signaling (via PI3K/Akt) takes over to promote differentiation and fusion of these progenitor cells into existing or new muscle fibers. The PEG moiety increases molecular size beyond the renal filtration threshold and creates a hydration shell that blocks proteolytic enzymes, extending bioactivity from minutes to days.
What to Expect
Satellite cell activation begins. Mild injection site reactions may occur. Improved subjective recovery from workouts reported by some users. No visible changes yet.
Noticeable reduction in delayed-onset muscle soreness (DOMS). Training capacity may increase as recovery improves. Early gains in muscle fullness reported.
Peak effects on muscle repair and growth become apparent. Measurable improvements in recovery time between sessions. Increased muscle density and hardness reported.
Receptor sensitivity reset period. Satellite cell pool remains expanded from the on-cycle priming. Maintain training stimulus to retain gains. Transition to other peptides if desired.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 150mcg | 2x/week |
| Moderate | 200mcg | 3x/week |
| Aggressive | 400mcg | 3x/week |
Note: PEGylated form of Mechano Growth Factor (IGF-1Ec splice variant). The PEG moiety extends half-life from minutes to days. Inject post-workout near the trained muscle for localized effects. Do not combine with IGF-1 LR3 in the same injection window — stagger by several hours.
How to Inject PEG-MGF
Inject subcutaneously or intramuscularly near the trained muscle within 30 minutes of completing a workout. For bilateral muscles (e.g., legs), split the dose between both sides. Use an insulin syringe for dosing accuracy. Avoid co-administering with IGF-1 LR3 at the same time — stagger by at least 4-6 hours, as both compete for satellite cell receptor binding.
Cycling Protocol
Cycle to prevent receptor desensitization. Most protocols use 4-8 weeks on, 2-4 weeks off. Inject on training days within 30 minutes post-workout for optimal satellite cell activation.
Pharmacokinetics
Source: Estimated from PEGylation pharmacokinetic principles; native MGF t1/2 ~5-7 min, PEGylated form ~48-72 hours. No direct human PK study available.
Loading the interactive decay curve.
Side Effects
Injection site reactions (pain, redness, swelling). Possible hypoglycemia at higher doses. Water retention and joint discomfort reported. Localized muscle tightness or cramping. Blood pressure fluctuations occasionally noted. Limited human safety data — most evidence is preclinical.
Contraindications
- Active malignancy or history of cancer (satellite cell stimulation may promote tumor growth)
- Pregnancy or breastfeeding (no safety data available)
- Active intracranial lesions or pituitary tumors
- Uncontrolled diabetes or severe hypoglycemia risk
- Severe hepatic or renal impairment (affects PEG-MGF metabolism and clearance)
- Known hypersensitivity to PEGylated compounds or MGF peptides
- Pre-existing musculoskeletal tumors or abnormal tissue growth
Drug Interactions
- IGF-1 LR3 — avoid simultaneous dosing; stagger by 4-6 hours to prevent receptor competition and allow sequential satellite cell activation then differentiation
- Exogenous growth hormone (HGH) — may amplify IGF-1 axis stimulation; monitor for excessive growth factor activity
- Insulin — combined hypoglycemia risk; monitor blood glucose closely if co-administering
- Glucocorticoids (prednisone, dexamethasone) — may impair satellite cell activation and blunt PEG-MGF efficacy
- Somatostatin analogs (octreotide) — may suppress downstream GH/IGF-1 signaling and reduce complementary effects
Storage & Stability
Molecular Profile
Related Peptides
References
- MGF E peptide activates human muscle progenitor cells and increases fusion potential at different ages (Mech Ageing Dev 2011)PubMed 21354439
- MGF promotes proliferation and inhibits differentiation of porcine satellite cells via MyoD down-regulation (Mol Cell Endocrinol 2012)PubMed 22875667
- Minireview: Mechano-growth factor — a putative product of IGF-I gene expression involved in tissue repair (Endocrinology 2010)PubMed 20130113
- Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? (J Physiol 2012)Review